As the global population ages, depression in older adults is increasingly common, yet conventional antidepressants often have limited effectiveness and problematic side effects. Psychedelic compounds are emerging as a potential alternative. This review examines preclinical and clinical evidence suggesting psychedelics could treat major depressive disorder in the elderly. It discusses the neurobiological mechanisms behind these effects, highlights relevant animal models, and addresses safety concerns. The authors propose strategies to improve the efficacy and safety of psychedelic therapy in future clinical trials, offering a new avenue for treating late-life depression.
This theoretical paper explores whether psychedelic-assisted therapy could address comorbidities often accompanying Alzheimer's disease, such as depression, anxiety, and social withdrawal. The authors argue that psychedelics may promote neuroplasticity, reduce inflammation, and facilitate psychological breakthroughs that improve quality of life. They suggest that combining psychedelic compounds with psychotherapy might offer a novel approach to managing behavioral and psychological symptoms of dementia. The paper calls for further research into safety, dosing, and ethical considerations for this vulnerable population, noting that current evidence is preliminary and based largely on extrapolation from studies in other conditions.